MedPage Today on MSN2d
Brain Edema, Imaging Abnormalities Reported for Alzheimer's Drug
Treatment with donanemab (Kisunla) raised the risk of amyloid-related imaging abnormalities (ARIA) in people with early ...
Visa, Eli Lilly, Blackstone And A Real Estate Stock On CNBC's 'Final Trades'
On Feb. 27, Blackstone disclosed that Rodney Zemmel – a long-time Senior Partner at McKinsey, who served as the global leader of both McKinsey Digital and the firm’s AI Transformation initiatives – ...
Fierce Pharma8d
In UK, it's strike 2 for Alzheimer's treatments from Lilly and Biogen/Eisai
England’s National Institute for Health and Care Excellence (NICE) has given a second thumbs down to a pair of Alzheimer’s ...
Where Will Eli Lilly Be in 5 Years?
It's hard to argue with the kinds of results Eli Lilly (NYSE: LLY) has produced over the past five years. Let's figure out ...
4BIIB, LLY : Alzheimer's Drugs From Eli Lilly And Biogen Still Deemed...
NICE has upheld its decision not to recommend Alzheimer's treatments donanemab and lecanemab for NHS use, citing high costs ...
Dr. Sanjay Gupta to headline Alzheimer's Drug Discovery Foundation summit in West Palm
Heidi McWilliams, a 10-year Palm Beach resident, is chair of the organization's inaugural event at the Palm Beach County ...
pharmaphorum2d
AstraZeneca to work with Lilly on Alzheimer's drug
Lilly and AZ have a rival in the BACE field – Merck's MK-8931 is currently in a phase 2/3 study treating patients with mild to moderate Alzheimer's. BACE offers hope ...